Can an immunotherapy combo shrink stomach tumors before surgery?

NCT ID NCT04354662

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether adding the immunotherapy drug toripalimab to a standard chemotherapy regimen (FLOT) before surgery can improve outcomes for people with locally advanced gastric cancer. Participants receive four cycles of the combination, then undergo surgery, and are followed for several years. The study aims to see if this approach increases the rate of complete tumor disappearance and improves long-term survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
toripalimab combined with FLOT chemotherapy (docetaxel, oxaliplatin, leucovorin, fluorouracil)
What this could lead to
If successful, this combination could improve the chance of eliminating the tumor before surgery and extend survival for people with gastric cancer.
What could go wrong
This is a small phase 2 trial, so results may not be conclusive. Adding immunotherapy to chemotherapy can increase side effects, and not all patients may benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.